Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Infinity Pharmaceuticals, Inc. INFI NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
27/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Infinity Pharmaceuticals, Inc. (INFI) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 8 Buy, 9 Hold.

INFI Analyst Ratings

Hold
17
Ratings
8 Buy
9 Hold
Based on 17 analysts giving stock ratings to Infinity Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
8 47%
Hold
9 53%
47%
Buy
8 analysts
53%
Hold
9 analysts
0%
Sell
0 analysts

People Also View

ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 TRVI
TRVI
Trevi Therapeutics, Inc.
$14.04
+5.33%
 NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CMRX
CMRX
Chimerix, Inc.
$8.54
+0.00%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message